Washington University School of Medicine in St. Louis and BJC Health System have launched the joint Center for Health AI. The center will focus on making care more personalized and effective for patients and more efficient and manageable for physicians, nurses and all those striving to ensure patients receive the very best care.

Washington University School of Medicine in St. Louis and BJC Health System have launched the joint Center for Health AI. The center will focus on making care more personalized and effective for patients and more efficient and manageable for physicians, nurses and all those striving to ensure patients receive the very best care.

The Academy of Science, Engineering and Medicine of Florida (ASEMFL) has named two Florida State University faculty members part of its 2024 class of "Rising Stars."

Shane L. Beckers, DVM, is a distinguished military veteran and medical professional with more than 20 years of experience in the veterinary industry

Regenerative medicine research efforts are set to strengthen in Australia with the recent announcement between Melbourne’s Monash University and leading US biomedical institution, MDI Biological Laboratory.

Dr. Declan Fox speaks with CBC News: Compass host Louise Martin about the conference, and some of the issues facing rural health care.

Unauthorised purchase of medicines and equipment from a private agency has come under the scanner of Central Bureau of Investigation (CBI) which is probing the financial irregularities in R.G. Kar Medical College and Hospital in Kolkata.

Bioethicist Wesley J. Smith joins Fr. Barnabas to discuss the growing problem of Euthanasia in our society.

It’s a bit like a supermarket manager dying of starvation or a bottled-water distributor dying of thirst: In the U.K., a former National Health Service (NHS) director died while waiting for medical care — at her own hospital. The Daily Mail reports:

Margaret Hutchon, a former mayor, had been waiting since last June for a follow-up stomach operation at Broomfield Hospital in Chelmsford, Essex.

But her appointments to go under the knife were cancelled four times and she barely regained consciousness after finally having surgery.

Her devastated husband, Jim, is now demanding answers from Mid Essex Hospital Services NHS Trust — the organisation where his wife had served as a non-executive member of the board of directors.

He said: "I don't really know why she died. I did not get a reason from the hospital. We all want to know for closure. She got weaker and weaker as she waited and operations were put off."

Not to be cruel, but the reason is simple.

It’s called government-run health care.

Autor: Redakcija 031 Naslov: Potpisan sporazum o suradnji između Akademije za umjetnost i kulturu u Osijeku i Hrvatske komore den
Postano: 12.11.2024. 11:59 (GMT 1) Dana 11. studenog 2024., točno u 11 sati i 11 minuta, u Svečanoj dvorani Akademije za umjetnost i kulturu u Osijeku potpisan je sporazum o suradnji između Akademije i Hrvatske komore dentalne medicine. Sporazum su uime institucija potpisali dekanica Akademije, akademkinja Helena Sablić Tomić, i dr. sc. Hrvoje Pezo, predsjednik Komore.

Sporazum označava početak suradnje između jedinstvene umjetničko-znanstvene institucije u zemlji i strukovne organizacije koja predstavlja dentalnu medicinu u Hrvatskoj. Cilj je sporazuma objediniti znanje i resurse kako bi se postigli viši standardi u razumijevanju i unaprjeđenju zajedničkih područja djelovanja koji se protežu kroz edukaciju, zdravstvo, kulturu i interdisciplinarne projekte koji se razvijaju na specijalističkom studiju Kreativnih terapija pri Akademiji za umjetnost i kulturu u Osijeku.

„Ovim partnerstvom želimo otvoriti nove mogućnosti suradnje u području obrazovanja i profesionalnog razvoja te omogućiti razmjenu iskustava između umjetničko-znanstvene zajednice i medicinske struke“, istaknula je akademkinja Helena Sablić Tomić. „Akademija i Komora mogu se zajedničkim naporima baviti istraživanjem novih pristupa u edukaciji kao i poticanjem šireg društvenog dijaloga o važnosti holističkog pristupa zdravlju.“

Predsjednik Komore dr. sc. Hrvoje Pezo naglasio je da sporazum predstavlja jedinstvenu priliku za razvoj novih standarda u edukaciji o zdravstvenoj kulturi i prevenciji. „Spoj umjetničkog i znanstvenog pristupa, uz medicinsku ekspertizu, omogućuje nam da dublje sagledamo utjecaj koji zdravlje ima na svakodnevni život, ali i na kulturu i društvenu dinamiku. Vjerujemo da će se kroz ovu suradnju razvijati inovativni pristupi obrazovanju i informiranju javnosti,“ izjavio je dr. Pezo.


Tekst i foto: Akademija za umjetnost i kulturu u Osijeku

[Lesotho Times] THE Ministry of Health, through its Department of Pharmaceuticals, has urged the public to use medicines safely and to report any side effects that they may feel after taking medications.

Symposia. ITMAT symposia enlist outstanding speakers from the US and abroad to address topics of direct relevance to translational science. Read more

Medical science in the 21st century is making strides in areas that once seemed like science fiction. As technology rapidly advances, we’re seeing new possibilities for improving health and longevity. From potential treatments for tooth loss to progress in curing genetic disorders, these innovations aim to address some of the significant health challenges we face […]

The post 10 Major Recent Advances in Medicine appeared first on Listverse.

In this episode, Fr. Tom talks about how we should view the practice of medicine and medication from an Orthodox Christian perspective.

The Holy Apostle’s fast is upon us. Fasting is not legalistic; rather, it is a medicine we choose to take to deepen our communion with God. Rita focuses on approaching the fast from a willing heart. She also discusses how joyful fasting can lead to health benefits.

Rita explores the use of modern day medicine and how it lines up with our Holy Orthodox Tradition.

the course of medication that cures Hepatitis C costs $84,000 at $1,000/pill, but can be produced for only $700 or $0.83/pill #

Returning to the podcast after a personal break, Wesley ask, "Can doctors and other healthcare providers be forced to provide medical proceeds, like abortions, when it goes against their convictions?"

Access to quality healthcare is a fundamental right but unfortunately, India suffers from gender disparities in healthcare access. Telemedicine has the potential to improve access to healthcare services for women by eliminating traditional barriers. Therefore, our research aims to investigate the factors influencing the adoption of telemedicine among Indian women. This study has collected 442 responses and analysed them through structural equation modelling. The result indicates a strong and positive connection between the willingness to adopt telemedicine services and factors like performance expectancy, perceived benefits, e-health literacy, and perceived reliability. Notably, perceived reliability emerges as the most impactful predictor, closely followed by perceived benefits, while factors like effort expectancy and user resistance show no significant influence. This underscores the pivotal role of reliability and perceived benefits in shaping women's inclination toward adopting telemedicine. The study provides practical insights for telemedicine providers and policymakers to customise strategies and policies for effective promotion.

Aim/Purpose: This study aims to devise a personalized solution for online healthcare platforms that can alleviate problems arising from information overload and data sparsity by providing personalized healthcare services to patients. The primary focus of this paper is to develop an effective medicine recommendation approach for recommending suitable medications to patients based on their specific medical conditions. Background: With a growing number of people becoming more conscious about their health, there has been a notable increase in the use of online healthcare platforms and e-services as a means of diagnosis. As the internet continues to evolve, these platforms and e-services are expected to play an even more significant role in the future of healthcare. For instance, WebMD and similar platforms offer valuable tools and information to help manage patients’ health, such as searching for medicines based on their medical conditions. Nonetheless, patients often find it arduous and time-consuming to sort through all the available medications to find the ones that match their specific medical conditions. To address this problem, personalized recommender systems have emerged as a practical solution for mitigating the burden of information overload and data sparsity-related issues that are frequently encountered on online healthcare platforms. Methodology: The study utilized a dataset of MC ratings obtained from WebMD, a popular healthcare website. Patients on this website can rate medications based on three criteria, including medication effectiveness, ease of use, and satisfaction, using a scale of 1 to 5. The WebMD MC rating dataset used in this study contains a total of 32,054 ratings provided by 2,136 patients for 845 different medicines. The proposed HSMCCF approach consists of two primary modules: a semantic filtering module and a multi-criteria filtering module. The semantic filtering module is designed to address the issues of data sparsity and new item problems by utilizing a medicine taxonomy that sorts medicines according to medical conditions and makes use of semantic relationships between them. This module identifies the medicines that are most likely to be relevant to patients based on their current medical conditions. The multi-criteria filtering module, on the other hand, enhances the approach’s ability to capture the complexity of patient preferences by considering multiple criteria and preferences through a unique similarity metric that incorporates both distance and structural similarities. This module ensures that patients receive more accurate and personalized medication recommendations. Moreover, a medicine reputation score is employed to ensure that the approach remains effective even when dealing with limited ratings or new items. Overall, the combination of these modules makes the proposed approach more robust and effective in providing personalized medicine recommendations for patients. Contribution: This study addresses the medicine recommendation problem by proposing a novel approach called Hybrid Semantic-based Multi-Criteria Collaborative Filtering (HSMCCF). This approach effectively recommends medications for patients based on their medical conditions and is specifically designed to overcome issues related to data sparsity and new item recommendations that are commonly encountered on online healthcare platforms. The proposed approach addresses data sparsity and new item issues by incorporating a semantic filtering module and a multi-criteria filtering module. The semantic filtering module sorts medicines based on medical conditions and uses semantic relationships to identify relevant ones. The multi-criteria filtering module accurately captures patient preferences and provides precise recommendations using a novel similarity metric. Additionally, a medicine reputation score is also employed to further expand potential neighbors, improving predictive accuracy and coverage, particularly in sparse datasets or new items with few ratings. With the HSMCCF approach, patients can receive more personalized recommendations that are tailored to their unique medical needs and conditions. By leveraging a combination of semantic-based and multi-criteria filtering techniques, the proposed approach can effectively address the challenges associated with medicine recommendations on online healthcare platforms. Findings: The proposed HSMCCF approach demonstrated superior effectiveness compared to benchmark recommendation methods in multi-criteria rating datasets in terms of enhancing both prediction accuracy and coverage while effectively addressing data sparsity and new item challenges. Recommendations for Practitioners: By applying the proposed medicine recommendation approach, practitioners can develop a medicine recommendation system that can be integrated into online healthcare platforms. Patients can then utilize this system to make better-informed decisions regarding the medications that are most suitable for their specific medical conditions. This personalized approach to medication recommendations can ultimately lead to improved patient satisfaction. Recommendation for Researchers: Integrating patient medicine reviews is a promising way for researchers to elevate the proposed medicine recommendation approach. By leveraging patient reviews, the approach can gain a more comprehensive understanding of how certain medications perform for specific medical conditions. Additionally, exploring the relationship between MC-based ratings using an improved aggregation function can potentially enhance the accuracy of medication predictions. This involves analyzing the relationship between different criteria, such as medication effectiveness, ease of use, and satisfaction of the patients, and determining the optimal weighting for each criterion based on patient feedback. A more holistic approach that incorporates patient reviews and an improved aggregation function can enable the proposed medicine recommendation approach to provide more personalized and accurate recommendations to patients. Impact on Society: To mitigate the risk of infection during the COVID-19 pandemic, the promotion of online healthcare services was actively encouraged. This allowed patients to continue accessing care and receiving treatment while adhering to physical distancing guidelines and shielding measures where necessary. As a result, the implementation of personalized healthcare services for patients is expected to be a major disruptive force in healthcare in the coming years. This study proposes a personalized medicine recommendation approach that can effectively address this issue and aid patients in making informed decisions about the medications that are most suitable for their specific medical conditions. Future Research: One way that may enhance the proposed medicine recommendation approach is to incorporate patient medicine reviews. Furthermore, the analysis of MC-based ratings using an improved aggregation function can also potentially enhance the accuracy of medication predictions.

Aim/Purpose: This research utilized a learn-to-rank algorithm to provide medical recommendations to prescribers. The algorithm has been utilized in other domains, such as information retrieval and recommender systems. Background: Ranking the possible medical treatments according to diagnoses of the medical cases is very beneficial for doctors, especially during the coding process. Methodology: We developed two deep learning pointwise learn-to-rank models within one prediction pipeline: one for predicting the top possible active ingredients from disease features, the other for ranking actual medicines codes from diseases and the ingredients features. Contribution: A new learn-to-rank deep learning model has been developed to rank medical procedures based on datasets collected from insurance companies. Findings: We ran 18 cross-validation trials on a confidential dataset from an insurance company. We obtained an average normalized discounted cumulative gain (NDCG@8) of 74% with a 5% standard deviation as a result of all 18 experiments. Our approach outperformed a known approach used in the information retrieval domain in which data is represented in LibSVM format. Then, we ran the same trials using three learn-to-rank models – pointwise, pairwise, and listwise – which yielded average NDCG@8 of 71%, 72%, and 72%, respectively. Recommendations for Practitioners: The proposed model provides an insightful approach to helping to manage the patient’s treatment process. Recommendation for Researchers: This research lays the groundwork for exploring various applications of data science techniques and machine learning algorithms in the medical field. Future studies should focus on the significant potential of learn-to-rank algorithms across different medical domains, including their use in cost-effectiveness models. Emphasizing these algorithms could enhance decision-making processes and optimize resource allocation in healthcare settings. Impact on Society: This will help insurance companies and end users reduce the cost associated with patient treatment. It also helps doctors to choose the best procedure and medicines for their patients. Future Research: Future research is required to investigate the impact of medicine data at a granular level.

.

The Australians’ hybrid soul and funk sound continues to impress.

“Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans,” the Nobel Assembly said.

The post Nobel Prize in medicine honors two Mass. professors for their discovery of microRNA appeared first on Boston.com.

This week Zorba and Karl discuss how doctors should balance traditional and alternative medicine, and they examine new research that explains why some people don’t experience COVID symptoms. Plus, they […]

This week Zorba and Karl discuss how certain foods can improve your mood, and they talk about the FDA claiming a decongestant in popular cold medicines doesn’t work at all. […]

HOK designed the Institute for Specialized Medicine & Intervention’s new clinic in Quebec as a spa-like experience for underserved patients. Supporting this modern, comforting, healing environment, HOK specified Rockfon Medical Plus acoustic stone wool ceiling panels for all of ISMI’s treatment rooms.

Washington – Although blast trauma among soldiers can be proven to cause serious eye injuries and may be linked to post-traumatic stress disorder, insufficient evidence exists showing a relationship to tinnitus, vertigo and cardiovascular issues, according to a new report from the Institute of Medicine.

RMI Access Telemedicine and Case Management provide 24/7 year-round access to licensed medical providers trained in industrial injury management in all 50 states. The telemedicine service gives workers access via chat or video – or telephone if internet service is unavailable.

The post ‘Facts that are declared proven’: sexual violence, forensic medicine, and the courtroom in early Francoist Spain. was curated by information for practice.

Catina Latham, PhD, will succeed Brenda Battle as UChicago Medicine's Senior Vice President for Community Health Transformation and Chief Equity Officer

; Credit: /Rose Wong for NPR/KHN

Claire Lang-Ree was in a lab coat taking a college chemistry class remotely in the kitchen of her Colorado Springs, Colo., home, when a profound pain twisted into her lower abdomen. She called her mom, Jen Lang-Ree, a nurse practitioner who worried it was appendicitis and found a nearby hospital in the family's health insurance network.

After a long wait in the emergency room of Penrose Hospital, Claire received morphine and an anti-nausea medication delivered through an IV. She also underwent a CT scan of her abdomen and a series of tests.

Hospital staffers ruled out appendicitis and surmised Claire was suffering from a ruptured ovarian cyst, which can be a harmless part of the menstrual cycle but can also be problematic and painful. After a few days — and a chemistry exam taken through gritted teeth — the pain went away.

Then the bill came.

Patient: Claire Lang-Ree, a 21-year-old Stanford University student who was living in Colorado for a few months while taking classes remotely. She's insured by Anthem Blue Cross through her mom's work as a pediatric nurse practitioner in Northern California.

Total Bill: $18,735.93, including two $722.50 fees for a nurse to "push" drugs into her IV, a process that takes seconds. Anthem's negotiated charges were $6,999 for the total treatment. Anthem paid $5,578.30, and the Lang-Rees owed $1,270.45 to the hospital, plus additional bills for radiologists and other care. (Claire also anted up a $150 copay at the ER.)

Service Provider: Penrose Hospital in Colorado Springs, part of the regional health care network Centura Health.

What Gives: As hospitals disaggregate charges for services once included in an ER visit, a hospitalization or a surgical procedure, there has been a proliferation of newfangled fees to increase billing. In the health field, this is called "unbundling." It's analogous to the airlines now charging extra for each checked bag or for an exit row seat. Over time, in the medical industry, this has led to separate fees for ever-smaller components of care. A charge to put medicine into a patient's IV line — a "push fee" — is one of them.

Though the biggest charge on Claire's bill, $9,885.73, was for a CT scan, in many ways Claire and her mom found the push fees most galling. (Note to readers: Scans are frequently many times more expensive when ordered in an ER than in other settings.)

"That was so ridiculous," says Claire, who adds she had previously taken the anti-nausea drug they gave her; it's available in tablet form for the price of a cup of coffee, no IV necessary. "It works really well. Why wasn't that an option?"

In Colorado, the average charge for the code corresponding to Claire's first IV push has nearly tripled since 2014, and the dollars hospitals actually get for the procedure has doubled. In Colorado Springs specifically, the cost for IV pushes rose even more sharply than it did statewide.

A typical nurse in Colorado Springs makes about $35 an hour. At that rate, it would take nearly 21 hours to earn the amount of money Penrose charged for a push of plunger that likely took seconds or at most minutes.

The hospital's charge for just one "IV push" was more than Claire's portion of the monthly rent in the home she shared with roommates. In the end, Anthem did not pay the push fees in its negotiated payment. But claims data shows that in 2020 Penrose typically received upward of $1,000 for the first IV push. And patients who didn't have an insurer to dismiss such charges would be stuck with them. Colorado hospitals on average received $723 for the same code, according to the claims database.

"It's insane the variation that we see in prices, and there's no rhyme or reason," says Cari Frank with the Center for Improving Value in Health Care, a Colorado nonprofit that runs a statewide health care claims database. "It's just that they've been able to negotiate those prices with the insurance company and the insurance company has decided to pay it."

To put the total cost in context, Penrose initially charged more money for Claire's visit than the typical Colorado hospital would have charged for helping someone give birth, according to data published by the Colorado Division of Insurance.

Even with the negotiated rate, "it was only $1,000 less than an average payment for having a baby," Frank says.

In an email statement, Centura said it "conducted a thorough review and determined all charges were accurate" and went on to explain that "an Emergency Room (ER) must be prepared for anything and everything that comes through the doors," requiring highly trained staff, plus equipment and supplies. "All of this adds up to large operating costs and can translate into patient responsibility."

As researchers have found, little stands in the way of hospitals charging through the roof, especially in a place like an emergency room, where a patient has few choices. A report from National Nurses United found that hospital markups have more than doubled since 1999, according to data from the United States Bureau of Labor Statistics. In an email, Anthem called the trend of increasing hospital prices "alarming" and "unsustainable."

But Ge Bai, an associate professor of accounting and health policy at Johns Hopkins University, says when patients see big bills it isn't only the hospital's doing — a lot depends on the insurer, too. For one, the negotiated price depends on the negotiating power of the payer, in this case, Anthem.

"Most insurance companies don't have comparable negotiating or bargaining power with the hospital," said Bai. Prices in a state like Michigan, where Bai said the UAW union covers a big proportion of Michigan patients, will look very different from those in Colorado.

Also, insurers are not the wallet defenders patients might assume them to be.

"In many cases, insurance companies don't negotiate as aggressively as they can, because they earn profit from the percentage of the claims," she says. The more expensive the actual payment is, the more money they get to extract.

Though Anthem negotiated away the push fees, it paid the hospital 30% more than the average Level IV emergency department visit in Colorado that year, and it paid quadruple what Medicare would allow for her CT scan.

Resolution: Claire and her mom decided to fight the bill, writing letters to the hospital and searching for information on what the procedures should have cost. The cost of the IV pushes and CT scan infuriated them — the hospital wanted more than double for a CT than what top-rated hospitals typically charged in 2019.

But the threat of collections wore them out and ultimately they paid their assigned share of the bill — $1,420.45, which was mostly coinsurance.

"Eventually it got to the point where I was like, 'I don't really want to go to collections, because this might ruin my credit score,'" says Claire, who didn't want to graduate from college with dinged credit.

Bai and Frank say the state of Maryland can provide a useful benchmark for medical bills, since it sets the prices that hospitals can charge for each procedure. Data provided by the Maryland Health Care Commission shows that Anthem and Claire paid seven times what she likely would have paid for the CT scan there, and nearly 10 times what they likely would have paid for the emergency department Level IV visit. In Maryland, intravenous pushes typically cost about $200 apiece in 2019. A typical Maryland hospital would have received only about $1,350 from a visit like Claire's, and the Lang-Rees would have been on the hook for about $270.

Claire's pain has come back a few times, but never as bad as that night in Colorado. She has avoided reentering an emergency room since then. After visiting multiple specialists back home in California, she learned she might have had a condition called ovarian torsion.

The Takeaway: Even at an in-network facility and with good insurance, patients can get hurt financially by visiting the ER. A few helpful documents can help guide the way to fighting such charges. The first is an itemized bill.

"I just think it's wrong in the U.S. to charge so much," says Jen Lang-Ree. "It's just a little side passion of mine to look at those and make sure I'm not being scammed."

Bai, of Johns Hopkins, suggests asking for an itemized explanation of benefits from the insurance company, too. That will show what the hospital actually received for each procedure.

Find out if the hospital massively overcharged. The Medicare price lookup tool can be useful for getting a benchmark. And publicly available data on health claims in Colorado and at least 17 other states can help, too.

Vincent Plymell with the Colorado Division of Insurance encourages patients to reach out if something on a bill looks sketchy. "Even if it's not a plan we regulate," he wrote in an email, departments such as his "can always arm the consumer with info."

Finally, make scrutinizing such charges fun. Claire and Jen made bill-fighting their mother-daughter hobby for the winter. They recommend pretzel chips and cocktails to boost the mood.

Bill of the Month is a crowdsourced investigation by KHN and NPR that dissects and explains medical bills. Do you have an interesting medical bill you want to share with us? Tell us about it!

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports 10/28/2024

Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XERTA) and its Cell Pouch technology could be the solution to existing challenges involving the delivery of medical treatments to patients, such as the ones described here.

Diabetic patients in resource-limited settings are having to revert back to one of the less favored, alternative ways to take insulin, via syringes or glass vials, because Danish pharmaceutical company, Novo Nordisk A/S (NVO:NYSE), will stop making its insulin pens, The Guardian reported. Patients generally prefer this method for dosing themselves with insulin, as shown in a 2024 survey, because it is more convenient and more accurate.

Type 1 diabetic patients already are being impacted as Novo stopped supplying its insulin pens to certain regions, South Africa for instance. Patients there have switched back to using glass vials.

In a second situation, Novo Nordisk is working to bring stem cell-based therapies to patients more efficiently and, in seeking a solution, formed a partnership with Evotec SE (EVO:NASDAQ) to develop technologies that will achieve this, noted Evotec is a Germany-based global biotech firm with its own cell therapy and partnered cell types all in preclinical development for various indications, including diabetes, oncology, cardiology, and ophthalmology.

Per the agreement, Novo Nordisk is to provide research and development funding and potentially monetary incentives to Evotec, and Evotec is to develop the desired new technologies. Novo has the option to obtain exclusive rights to use, in a predefined medical indication, the product(s) born out of this collaboration agreement. Novo's areas of focus, along with diabetes, are cardiovascular diseases, rare diseases, growth hormone-related diseases, hemophilia, nonalcoholic steatohepatitis, and weight management.

Safe, Effective Therapeutic Cell Delivery

Sernova Corp.'s Cell Pouch is a vehicle for delivering various types of therapeutic cells to patients, such as donor islet cells to insulin-dependent diabetics.

When used, the Cell Pouch's containment channels are filled with the appropriate therapeutic cells, and then the device is implanted in the patient. In situ, the cells release therapeutic proteins or hormones the patient's body completely or partially lacks. The device creates a vascularized, organ-like environment that protects the therapeutic cells from immune system attacks, keeping them alive and functioning.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote in a Sept. 12 research report.

Sernova is testing its Cell Pouch in the clinic, specifically in Type 1 diabetes. In its ongoing Phase 1/2 study, the Canadian company is evaluating the treatment of insulin-dependent diabetes with donor islets implanted via the Cell Pouch, with added immunosuppression therapy. Study data so far have shown the Cell Pouch to be safe and well tolerated and the treatment, effective, reported Dr. Joseph Pantginis, analyst at H.C. Wainwright & Co., in a Sept. 12 research report.

Seven patients, all six of Cohort A and one in Cohort B, achieved sustained insulin independence, between 5.5 and 50 months in duration, free of hypoglycemic episodes. Their blood sugar levels were controlled in the nondiabetic range (i.e.,) HbA1c less than 6.5%.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote.

A Cell Pouch removed from one of the study patients showed it still contained functioning insulin, glucagon, and somatostatin-producing cells. No evidence was seen of detrimental fibrotic tissue, too many T-cells, material degradation, or changes in the device architecture.

"We believe the impressive response rates and observed durability support Sernova's strategy and justify further investigation while positioning the technology for potential commercial success," noted Pantginis.

The results add to an expanding collection of evidence that the Cell Pouch is functioning as it should. The data also support the "impressive" results already reported from this study and help derisk future related trials.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund in a Sept. 16 note.

In another of its programs, Sernova, in collaboration with Evotec, is developing an implantable off-the-shelf, induced pluripotent stem cell (iPSC)-based islet replacement therapy, Maund reported.

"This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2)," he added.

This partnership was announced on May 17, 2022. You can read more about it in the press release here.

Market Growth Predicted to 2030

The global live cell encapsulation market, encompassing drug delivery, regenerative medicine and cell transplantation, is expected to continue growing through at least 2030, according to Grand View Research. The market's value, US$210.7 million in 2022, is forecasted to increase at a 3.97% compound annual growth rate between that year and 2030.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund.

Along with diabetes, live cell encapsulation is being used to treat neurological disorders like Parkinson's disease, The market research firm noted. Further, it has been proven to be a suitable way to deliver treatment for other types of diseases, including cancer, anemia, heart failure and more.

Several factors are expected to keep driving market growth during the forecast period, Grand View noted. A significant one is the increasing use of live cell encapsulation in regenerative medicine to replace disease or damaged tissues. A related contributor is rising public and private funding and investments in cell and gene therapies.

The advantages of live cell encapsulation in controlled drug delivery are boosting the market, too. They include enhanced therapeutic effects, lowered drug dose, reduced cytotoxicity, improved patient convenience and better patient compliance.

Novel new products and technological advancements are expected to add value to the market as well.

The Catalysts: Progress With Programs

Various potential stock-moving events are slated for Sernova, according to its September 2024 Corporate Presentation.

Two catalysts are expected by Sernova in 2025, related to the company's ongoing Phase 1/2 clinical trial in Type 1 diabetes. One is results for the remaining Cohort B patients. The other is commencement of Cohort C, who will receive, along with the islet cells, an optimized immune suppression regimen.

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

Next year, Sernova plans to start a Phase 1/2 trial of the regeneratively produced islet cells to result from its partnership with Evotec, delivered via the Cell Pouch to Type 1 diabetes patients.

Other catalysts are expected to come as a result of Sernova advancing its preclinical programs. One is a personalized treatment with patient corrected cells via Cell Pouch for hypothyroidism. Another is a Cell Pouch-delivered, ex vivo lentiviral factor VIII gene therapy for hemophilia, being developed in partnership with the European Haemacure Consortium.

Also, through partnerships, Sernova is developing technologies that would eliminate the need for concurrent immunosuppression during Cell Pouch-delivered cell treatment, a "blue sky objective," Douglas Loe, a Leede Financial Inc. analyst, noted in a Sept. 12 research report.

"Any advances in this regard could be incorporated into future Cell Pouch studies," he wrote. "We do not consider the need for such therapy to be relevant to Cell Pouch function itself."

Analyst: Company is "Very Undervalued"

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

According to H.C. Wainwright's Pantginis, the deepening responses of Type 1 diabetes patients in its Phase 1/2 trial continue to "crystallize Sernova stock's possible upside." The upside reflected in Pantginis' price target is 2,122%. The analyst recommends the company as a Buy.

Ventum's Quenneville also has a Buy on Sernova, and his target price reflects an 826% return on investment. In his report, the analyst highlighted the impressive efficacy and tolerability of the Cell Pouch up to five years post-implantation, as shown in the Phase 1/2 clinical trial data.

"This represents the longest-lasting implanted encapsulation device containing functioning islets without fibrosis," Quenneville wrote.

According to Technical Analyst Maund, Sernova is "very undervalued here given its huge potential" in the Type 1 diabetes market, as indicated on the stock charts. The fundamental outlook for the company is improving, and evidence is strong that a reversal to the upside may be happening. SVA may appreciate significantly soon. [OWNERSHIP_CHART-4790]

"Sernova is therefore viewed as a good stock to accumulate in this area, between the current price and recent lows," Maund wrote on Sept. 16. At that time, Sernova's share price was about the same as it is now.

Ownership and Share Structure

According to Refinitiv, about 12.96% of the company is held by insiders and management, and 0.05% by institutions. The rest is retail.

Top shareholders include Tomas Angel with 4.91%, Director Steven Sangha with 4.27%, Betty Anne Millar with 1.32%, Brett Alexander Whalen with 0.87%, and Garry Deol with 0.77%.

Its market cap is CA$83 M. Its 52-week range is CA$0.20−0.82 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Sernova Corp. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Corp.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

( Companies Mentioned: SVA:TSX.V;SEOVF:OTCQB;PSH:XERTA, )

Marijuanas active components are potentially effective in treating pain, nausea, the anorexia of AIDS wasting, and other symptoms, and should be tested rigorously in clinical trials.

Good morning and welcome. There has been unprecedented interest in recent years about whether marijuana or its constituent compounds should be used as medicine. Since 1996, voters in seven states have approved the medical use of marijuana.

A new data network that integrates emerging research on the molecular makeup of diseases with clinical data on individual patients could drive the development of a more accurate classification of disease and ultimately enhance diagnosis and treatment, says a new report from the National Research Council.

The Institute of Medicine today presented the 2012 Gustav O. Lienhard Award to Donald M. Berwick, a physician whose work has catalyzed a national movement to improve health care quality and safety.

The Institute of Medicine today presented the Gustav O. Lienhard Award to Linda Aiken, Claire M. Fagin Leadership Professor of Nursing at the University of Pennsylvania School of Nursing, for her rigorous research demonstrating the importance of nursing care and work environments in achieving safe, effective, patient-centered, and affordable health care.

The National Academy of Sciences and the National Academy of Medicine are launching a major initiative to guide decision making about controversial new research involving human gene editing.

To make the world safer against future infectious disease threats, national health systems should be strengthened, the World Health Organization’s emergency and outbreak response activities should be consolidated and bolstered, and research and development should be enhanced, says a new Policy Forum article that appears in the May 19 edition of PLOS Medicine.

In response to alarming evidence of high rates of depression and suicide among U.S. health care workers, the National Academy of Medicine is launching a wide-ranging “action collaborative” of multiple organizations to promote clinician well-being and resilience.

The National Academies Committee on Genetically Engineered Crops - Past Experiences and Future Prospects authored an almost 600-page landmark report, released in May 2016. It was perhaps the most comprehensive analysis of genetically engineered crops to date.

As the nation discusses repealing and replacing the Affordable Care Act, the National Academy of Medicine today released a publication on crosscutting priorities that provides a succinct blueprint to address challenges to Americans’ health and health care that span beyond debates over insurance coverage.

Halting the opioid epidemic requires aggressive action across multiple dimensions, including informed, active, and determined front-line leadership from health clinicians working in every setting throughout the nation, says a new National Academy of Medicine (NAM) special publication developed at the request of the National Governors Association to assist the nation’s governors as they work with clinicians to counter the opioid crisis.